Genetic cause of hyperglycaemia and response to treatment in diabetes
Pearson, E. R.
Starkey, B. J.
Powell, R. J.
Gribble, F. M.
Clark, P. M.
Hattersley, A. T.
Rights© 2003 Elsevier Ltd. All rights reserved.
MetadataShow full item record
BACKGROUND: Type 2 diabetes shows evidence of underlying heterogeneity. No studies have assessed whether different causes for diabetes change the response to oral hypoglycaemic therapy. In a few cases, patients with diabetes caused by mutations in the hepatocyte nuclear factor 1alpha (HNF-1alpha) gene have been described as sensitive to the hypoglycaemic effects of sulphonylureas. We aimed to see whether the glycaemic response to the sulphonylurea gliclazide and the biguanide metformin differed in HNF-1alpha diabetes and type 2 diabetes, and to investigate the mechanism for differences in sulphonylurea sensitivity. METHODS: We did a randomised crossover trial of glicazide and metformin in 36 patients, either with diabetes caused by HNF-1alpha mutations or type 2 diabetes, who were matched for body-mass index and fasting plasma glucose. The primary outcome was reduction in fasting plasma glucose. Analysis was by intention to treat. We assessed possible mechanisms for sulphonylurea sensitivity through insulin sensitivity, insulin secretory response to glucose and tolbutamide, and tolbutamide clearance. FINDINGS: Patients with HNF-1alpha diabetes had a 5.2-fold greater response to gliclazide than to metformin (fasting plasma glucose reduction 4.7 vs 0.9 mmol/L, p=0.0007) and 3.9-fold greater response to gliclazide than those with type 2 diabetes (p=0.002). Patients with HNF-1alpha diabetes had a strong insulin secretory response to intravenous tolbutamide despite a small response to intravenous glucose, and were more insulin sensitive than those with type 2 diabetes. Sulphonylurea metabolism was similar in both patient groups. INTERPRETATION: The cause of hyperglycaemia changes the response to hypoglycaemic drugs; HNF-1alpha diabetes has marked sulphonylurea sensitivity. This pharmacogenetic effect is consistent with models of HNF-1alpha deficiency, which show that the beta-cell defect is upstream of the sulphonylurea receptor. Definition of the genetic basis of hyperglycaemia has implications for patient management.
NoteRD&E staff can access the full-text of this article by clicking on the 'Additional Link' above and logging in with NHS OpenAthens if prompted.
Showing items related by title, author, creator and subject.
A Whole-Blood Transcriptome Meta-Analysis Identifies Gene Expression Signatures of Cigarette Smoking. Huan, T.; Joehanes, R.; Schurmann, C.; Schramm, K.; Pilling, L. C.; Peters, M. J.; Mägi, R.; DeMeo, D.; O'Connor, G. T.; Ferrucci, L.; Teumer, A.; Homuth, G.; Biffar, R.; Völker, U.; Herder, C.; Waldenberger, M.; Peters, A.; Zeilinger, S.; Metspalu, A.; Hofman, A.; Uitterlinden, A. G.; Hernandez, D. G.; Singleton, A. B.; Bandinelli, S.; Munson, P. J.; Lin, Ho.; Benjamin, E.J.; Esko, T.; Grabe, H. J.; Prokisch, H.; van Meurs, J. B. J.; Melzer, David; Levy, D. (Oxford Journals, 2016-08-29)Cigarette smoking is a leading modifiable cause of death worldwide. We hypothesized that cigarette smoking induces extensive transcriptomic changes that lead to target-organ damage and smoking-related diseases. We performed ...
Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension Surendran, P [et al]; Yaghootkar, Hanieh (Nature, 2016-09-12)High blood pressure is a major risk factor for cardiovascular disease and premature death. However, there is limited knowledge on specific causal genes and pathways. To better understand the genetics of blood pressure, we ...
Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation. Spyer, G.; Macleod, K. M.; Shepherd, Maggie; Ellard, Sian; Hattersley, Andrew T. (Wiley, 2009-01)To assess determinants of fetal growth in the offspring of pregnant women with hyperglycaemia due to a heterozygous glucokinase (GCK) gene mutation.